PALM BEACH, Florida, January 3, 2018 /PRNewswire/ --
Accordingto Arcview Market Research, North Americans spent $6.7 billion on legal pot in 2016, up more than 30% from the year before and is forecast to grow to more than $24 billion by 2025. And as recreational
Future Farm Technologies Inc. (OTCQB: FFRMF) (CSE: FFT.CN) is pleased to provide an update to its current and prospective Shareholders regarding the Company's activities over the past several months, and plans for development in the new year.
Future Farm has experienced a flurry of activity in the past several weeks and the market has responded positively to our continued efforts to create a diversified portfolio of cannabis investments for Future Farm's shareholders. We have successfully raised capital to support the various projects that we are developing throughout North America, including those in California, Maine, Florida, Rhode Island, Puerto Rico and beyond.
Future Farm shareholders have raised $1.4 Million through the voluntary conversion of both its $0.35 and $0.37 warrants from two offerings in 2017, and as most recently announced, the completion of a $4,000,000 private placement with Yorkville Advisors that enables the Company to close on the acquisition of a 10-acre operating greenhouse in Florida. Read the entire detailed update along with more news for Future Farm at: http://www.marketnewsupdates.com/news/ffrmf.html
Additional developments in the industry today include:
Cannabis Wheaton Income Corp. (OTCQB: CBWTF) (TSX-V: CBW.V) recently announced the signing of its definitive agreement with streaming partner Canntx Life Sciences Inc. Further to its previously announced interim agreement, Cannabis Wheaton Income Corp. (doing business as Wheaton Income) has entered into a definitive agreement with its streaming partner CannTx Life Sciences Inc. to finance the construction of its cannabis production facility located in Puslinch, Ont. CannTx is a privately owned company that has applied to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations (ACMPR). Health Canada has confirmed that it has completed its paper review of the application and that CannTx needs to submit a confirmation of readiness to demonstrate that the facility is eligible for licensing.
Abattis Bioceuticals Corp. (OTCQB: ATTBF) (CSE: ATT.CN) recently announced an update on its previously announced proposed acquisition of GT Therapeutics Corporation, dba Green Tree Therapeutics ("GTT"). Over the past month, the Company has successfully raised over $8,500,000 in private placements and warrant exercises. These funds are expected to be used to aggressively grow the extraction business, and for laboratory expansion, acquisitions and general working capital. "We are very pleased with the rapid growth and positive momentum in Abattis," commented Rob Abenante, Chief Executive Officer of Abattis. "Many of the goals we have been working towards over the year are starting to come to fruition, which has enabled the company to raise capital that we intend to use to continue our ambitious growth strategy in 2018."
Aurora Cannabis Inc. (OTCQX: ACBFF) (TSX: ACB.TO) yesterday purchased 116,000 common shares of CanniMed Therapeutics Inc. The purchases were made in connection with Aurora's previously announced offer to purchase all of the common shares of CanniMed (the "Offer"). Aurora announced its intention to purchase common shares of CanniMed (the "CanniMed Shares") in its Offer to Purchase and Takeover Bid Circular dated November 24, 2017, which is filed on SEDAR under CanniMed's SEDAR profile. CanniMed implemented a shareholder rights plan on November 28, 2017, which prevented Aurora from commencing purchases in a timely fashion. The Ontario Securities Commission and the Saskatchewan Financial and Consumer Affairs Authority, in joint decisions dated December 22, 2017 and issued on December 27, 2017, cease traded the CanniMed rights plan.
GB Sciences Inc. (OTCQB: GBLX) closed up Tuesday over 20% at $1.02 trading over 5 million shares by the market close. Last month, the company announced its development of a cannabis strain that has an extremely high THC concentration, and also has a specifically-defined terpene profile, meaning that this potent strain may have significant medical benefits. The team was gratified to receive hard test results that verified their goal. The plant produced a THC-a content of 35.119%, as well as ?-myrcene levels of 2.18% and ?-caryophyllene levels of 1.01%, as tested by independent lab Digipath Labs, Inc. in Las Vegas. "Because of our research background, we're not willing to talk about things while we have only anecdotal evidence. But now, we have solid data that shows that the innovations that we have been working on for years are starting to bear fruit," said Chief Science Office, Dr. Andrea Small-Howard.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated twenty-four hundred dollars for news coverage of the current press release issued by Future Farm Technologies Inc by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Contact Information: firstname.lastname@example.org +1(561)325-8757
Subscribe to our Free Newsletters!
Blood groups are of four important groups determined by the presence or absence of specific ...
Spermatocele is a condition in which there is a blockage in the epididymal duct, resulting in semen ...
Be a blood donor and save lives for your donated blood is separated into blood products or just ...View All